Bispecifics
Autoimmune Diseases
IND-EnablingPreclinical
Key Facts
About Shattuck Labs
Shattuck Labs is a public biotech company focused on developing novel DR3-targeting antibodies to treat inflammatory diseases, with a primary focus on Inflammatory Bowel Disease (IBD). Its lead program, SL-325, is in Phase 2 development and represents the first clinical-stage DR3 blocking antibody, which the company believes offers potential advantages over competing TL1A-targeting therapies. The company's strategy is built on the scientific premise that blocking the receptor (DR3) rather than the ligand (TL1A) may lead to superior efficacy and reduced immunogenicity. Shattuck is headquartered in the United States with R&D operations in Durham, North Carolina, and a corporate office in Austin, Texas.
View full company profileTherapeutic Areas
Other Autoimmune Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Inflammation & Immunology Programs | Pfizer | Phase 2/3 |
| ARGX-118 | Argenx | Phase 1 |
| Adalimumab biosimilar (IBI303) | Innovent Biologics | Approved |
| Hulio (Adalimumab) | Biocon | Approved |
| Undisclosed ImmTAAI candidates | Immunocore | Preclinical |
| BHV-1100 (IgG degrader) | Biohaven | Preclinical |
| Preclinical Pipeline | Autolus Therapeutics | Pre-clinical |
| FT839 | Fate Therapeutics | Phase 1 |
| IMP761 | Immutep | Phase 1 (planned) |